As the treatment strategies are considered individually for each patient with Parkinson’s disease, it is reassuring for both clinicians and patients that the results from this MTC analysis indicate that all of the included dopamine agonists and MAO-B inhibitors, except safinamide, are effective compared with placebo. The gene discussed is MAOB; the disease is Parkinson disease.